Poseida Therapeutics Sees Unusually High Options Volume (NASDAQ:PSTX)

Poseida Therapeutics, Inc. (NASDAQ:PSTX) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 5,174 put options on the company. This represents an increase of approximately 3,372% compared to the average daily volume of 149 put options.

Analysts Set New Price Targets

PSTX has been the subject of several research analyst reports. BTIG Research reissued a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday. Cantor Fitzgerald downgraded Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday. William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 price objective (down previously from $20.00) on shares of Poseida Therapeutics in a report on Tuesday. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.50.

Poseida Therapeutics Stock Performance

Shares of PSTX stock opened at $9.33 on Thursday. The company has a market cap of $909.35 million, a P/E ratio of -14.81 and a beta of 0.54. The business has a 50 day moving average of $3.02 and a two-hundred day moving average of $3.01. Poseida Therapeutics has a 52 week low of $1.87 and a 52 week high of $9.42. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68.

Insider Buying and Selling at Poseida Therapeutics

In other news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total value of $278,100.00. Following the completion of the sale, the chairman now owns 651,291 shares of the company’s stock, valued at approximately $6,037,467.57. The trade was a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its position in Poseida Therapeutics by 53.4% in the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after buying an additional 297,500 shares during the period. Vanguard Group Inc. grew its position in shares of Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after acquiring an additional 473,746 shares during the last quarter. Advantage Alpha Capital Partners LP acquired a new stake in shares of Poseida Therapeutics in the 3rd quarter worth about $285,000. Public Employees Retirement System of Ohio lifted its position in Poseida Therapeutics by 177.3% in the 1st quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after purchasing an additional 40,245 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its stake in Poseida Therapeutics by 280.3% during the 1st quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock valued at $91,000 after purchasing an additional 21,138 shares during the period. Institutional investors and hedge funds own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.